Change of hematologic compartments and cell populations after Gfi1b deletion and NAC injection
| . | Gfi1bfl/fl . | Gfi1bfl/flMx-Cre tg . | Fold change . | P . |
|---|---|---|---|---|
| Number of BM cells ×106 NAC treatment | 45 ± 4 (n = 7) | 44 ± 2 (n = 6) | 1 | .8 |
| Number of splenocytes ×106 NAC treatment | 86 ± 22 (n = 4) | 104 ± 22 (n = 5) | 1.2 | .5 |
| % Lin− cells in BM NAC treatment | 1.5 ± 0.1 (n = 7) | 2.45 ± 0.5 (n = 6) | 1.6 | .15 |
| Number of Lin− cells ×106 NAC treatment | 0.8 ± 0.1 (n = 7) | 1.1 ± 0.4 (n = 6) | 1.4 | .32 |
| Number of HSCs in BM NAC treatment | 1700 ± 700 (n = 7) | 5700 ± 1100 (n = 6) | 3 | .01 |
| Number of HSCs in spleen NAC treatment | 197 ± 77 (n = 3) | 6000 ± 2000 (n = 4) | 30 | .07 |
| Number of HSCs per 1 mL of blood NAC treatment | 11 ± 1 (n = 3) | 307 ± 100 (n = 5) | 28 | .03 |
| . | Gfi1bfl/fl . | Gfi1bfl/flMx-Cre tg . | Fold change . | P . |
|---|---|---|---|---|
| Number of BM cells ×106 NAC treatment | 45 ± 4 (n = 7) | 44 ± 2 (n = 6) | 1 | .8 |
| Number of splenocytes ×106 NAC treatment | 86 ± 22 (n = 4) | 104 ± 22 (n = 5) | 1.2 | .5 |
| % Lin− cells in BM NAC treatment | 1.5 ± 0.1 (n = 7) | 2.45 ± 0.5 (n = 6) | 1.6 | .15 |
| Number of Lin− cells ×106 NAC treatment | 0.8 ± 0.1 (n = 7) | 1.1 ± 0.4 (n = 6) | 1.4 | .32 |
| Number of HSCs in BM NAC treatment | 1700 ± 700 (n = 7) | 5700 ± 1100 (n = 6) | 3 | .01 |
| Number of HSCs in spleen NAC treatment | 197 ± 77 (n = 3) | 6000 ± 2000 (n = 4) | 30 | .07 |
| Number of HSCs per 1 mL of blood NAC treatment | 11 ± 1 (n = 3) | 307 ± 100 (n = 5) | 28 | .03 |
The number of bone marrow (BM) cells, splenocytes, and % of Lin− cells was determined in wt and Gfi1b deficient mice. Mice were fed daily with N-Acetylcystein. HSCs are defined by immunophenotype as Lin−, Sca-1+, Kit+, CD150+, CD48−. Depicted are mean values, SEM, and number of samples. P values are based on unpaired 2-sided t test.